One big, happy family of firms is the goal; but skeptics foresee internal squabbling
Yet skeptics are wondering if the disparate biotech constituencies represented by these two organizations, which have feuded in the past, will be able to set aside their differences to join in a truly united effort. Further fueling skepticism in some quarters is the fact that the man appointed as president of the merged organization, Carl B. Feldbaum, former chief of staff to Sen. Arlen Specter (R-Pa.), has no direct biotech experience-- although those...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?